{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:53:01Z","timestamp":1790801581946,"version":"4.1.0"},"reference-count":30,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Dermatology"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Janus kinase inhibitors (JAKi) are drugs that block tyrosine kinases responsible for transducing cytokine signals. The first JAKi was approved by the US Food and Drug Administration (FDA) in 2011 to treat rheumatoid arthritis in adults. A pediatric indication was not approved until 8\u2009years later, for acute graft\u2010versus\u2010host disease. Since then, topical and oral formulations have gained FDA approval for pediatric patients with dermatologic diseases. While increasing evidence supports the safety of these medications in adults, data are limited in children. We sought to determine whether JAKi adverse events (AEs) as reported in clinical trials and via postapproval pharmacovigilance services are comparable in adult and pediatric patients. Pharmacovigilance data were extracted from the FDA's Adverse Event Reporting System and the Canada Vigilance Adverse Reaction Online Database for baricitinib, upadacitinib, abrocitinib, ruxolitinib, and tofacitinib. The pooled data were analyzed to detect the most common AEs for specific JAKi and for the drug class. We assessed 399,649 AEs from 133,216 adults and 2883 AEs from 955 patients under 18\u2009years old and identified slightly different AE profiles for the two age groups. Both populations had increased risk for infections and gastrointestinal AEs. However, pediatric patients reported a higher proportion of blood and lymphatic disorders, while reports of nervous system and musculoskeletal\/connective tissue disorders were more common in adults. The spectrum of AEs extracted from pharmacovigilance reports was similar to clinical trials. The JAKi AE profiles we observed may prove helpful in counseling patients and their parents before starting therapy and for monitoring once patients are on therapy.<\/jats:p>","DOI":"10.1111\/pde.15721","type":"journal-article","created":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T11:59:40Z","timestamp":1725537580000},"page":"1040-1046","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Analysis of publicly available adverse events reported for pediatric patients treated with <scp>Janus kinase<\/scp> inhibitors"],"prefix":"10.1111","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2462-3299","authenticated-orcid":false,"given":"Sahithi","family":"Talasila","sequence":"first","affiliation":[{"name":"Sidney Kimmel Medical College, Thomas Jefferson University  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Lee","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Medical College, Thomas Jefferson University  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6627-6550","authenticated-orcid":false,"given":"Eric M.","family":"Teichner","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Medical College, Thomas Jefferson University  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4794-9905","authenticated-orcid":false,"given":"Elaine C.","family":"Siegfried","sequence":"additional","affiliation":[{"name":"Saint Louis University and SSM Cardinal Glennon Children's Hospital  St. Louis Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie R.","family":"Jackson Cullison","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Cutaneous Biology Thomas Jefferson University  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,9,5]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.5070\/D329260765"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1202117"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm909"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.08.008"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvp.12101"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003668"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3895"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2016.03.008"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.463"},{"issue":"3","key":"e_1_2_10_11_1","first-page":"192","article-title":"SOTYKTUTM (Deucravacitinib 6\u2010mg tablets)\u2010 a new agent for the Management of Adult Plaque Psoriasis","volume":"21","author":"Gupta AK","year":"2023","journal-title":"Skinmed"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257\u2010017\u20100306\u20109"},{"key":"e_1_2_10_13_1","volume-title":"Healio Rheumatology","author":"Laday J"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.201"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130683"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25575"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon.14.272"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard\u20102022\u2010222543"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.222471"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917635"},{"key":"e_1_2_10_21_1","volume-title":"Fact Sheet for Healthcare Providers Emergency Use Authorization (EUA) of Baricitinib","author":"Eli Lilly and Company","year":"2020"},{"key":"e_1_2_10_22_1","volume-title":"E11A Pediatric Extrapolation","author":"Center for Drug Evaluation and Research","year":"2022"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010022\u201010777\u2010w"},{"issue":"1614","key":"e_1_2_10_24_1","first-page":"202","article-title":"For baricitinib (Olumiant) for COVID\u201019","volume":"62","author":"An EUA","year":"2020","journal-title":"Med Lett Drugs Ther"},{"key":"e_1_2_10_25_1","unstructured":"Highlights of Prescribing Information.https:\/\/www.rxabbvie.com\/pdf\/rinvoq_pi.pdf."},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/10600280221096713"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2022.104499"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.31138\/mjr.31.1.100"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.3830"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1799975"},{"key":"e_1_2_10_31_1","article-title":"What Is Your IQ(VIA)?","volume":"14","author":"Nash DB","year":"2021","journal-title":"Am Health Drug Benefits"}],"container-title":["Pediatric Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pde.15721","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T08:56:29Z","timestamp":1732092989000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/pde.15721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,5]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1111\/pde.15721"],"URL":"https:\/\/doi.org\/10.1111\/pde.15721","archive":["Portico"],"relation":{},"ISSN":["0736-8046","1525-1470"],"issn-type":[{"value":"0736-8046","type":"print"},{"value":"1525-1470","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,5]]},"assertion":[{"value":"2024-01-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}